The T790M “gatekeeper” mutation in <i>EGFR</i> mediates resistance to low concentrations of an irreversible EGFR inhibitor
Nadia Godin-Heymann(Harvard University), Daniel A. Haber(Howard Hughes Medical Institute), Shyamala Maheswaran(Massachusetts General Hospital), Ultan McDermott(AstraZeneca (United Kingdom)), Jeffrey Settleman(Harvard University), Jennifer Lamb(Harvard University), Lindsey Ulkus(Harvard University), Brian W. Brannigan(Harvard University)
Cited by 205